Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.

@article{Passardi2015ImpactOP,
  title={Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.},
  author={Alessandro Passardi and Emanuela Scarpi and Stefano Tamberi and Luigi Cavanna and Davide Tassinari and Annalisa Fontana and Sara Pini and Ilaria Bernardini and Caterina Accettura and Paola Ulivi and Giovanni Luca Frassineti and Dino Amadori},
  journal={PloS one},
  year={2015},
  volume={10 8},
  pages={e0134732}
}
BACKGROUND To investigate the impact of pre-treatment lactate dehydrogenase (LDH) levels on the outcome of patients with metastatic colorectal cancer treated with first-line chemotherapy with or without the anti-VEGF monoclonal antibody, bevacizumab, in a phase III prospective multicentre randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial. METHODS Three hundred and seventy patients enrolled onto the ITACa first-line trial were considered for this study, 176 receiving… CONTINUE READING
Highly Cited
This paper has 21 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Similar Papers

Loading similar papers…